Why Is VERACYTE INC (VCYT) Stock Down Today?

Veracyte Inc (VCYT) shares fell 22.52% to $46.32 in afternoon trading on Friday. The decline followed a downgrade from Canaccord, which cut the stock's price target to $50 amid concerns over the company’s revenue outlook. The move came despite recent strong earnings and guidance upgrades.

What Happened

Canaccord’s revised price target of $50 reflects a more cautious stance on Veracyte’s near-term revenue potential. This downgrade occurred within a broader market context where large stocks including Apple and Coinbase also declined in pre-market activity. Meanwhile, Needham maintained a Buy rating on Veracyte but raised its price target to $69, highlighting a divergence in analyst sentiment. Veracyte itself had recently raised its full-year 2026 sales guidance to a range of $590.000M to $596.000M, slightly above the $586.445M consensus estimate. The company also reported Q2 adjusted earnings per share of $0.54, exceeding the $0.24 estimate, and revenue of $150.321M, beating the $144.554M forecast. Despite these positive results, the stock has been pressured by recent insider selling and a broader downward trend.

What The Data Shows

Over the past eight trading sessions, VCYT has declined 20.2% from $58.01 to $46.32. Insiders have sold 7 times in the last 90 days, totaling $9.7M, with the most recent filing on June 22. Congressional activity includes two purchases by Rep. Gilbert Cisneros between February and April. The stock has a beta of 1.93, indicating high volatility, and trades at a P/E of 33.2 with a 52-week range of $22.92 to $60.91.

What To Watch

Veracyte does not have an upcoming earnings date in the immediate outlook. Investors should monitor the breadth of analyst coverage and any further guidance adjustments from the company.